Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | MAP3K12 | Q12852 | 4/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL163161 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9MAP3K12ROCK2 | |
| SCHEMBL196669 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9MAP3K12ROCK2 | |
| SCHEMBL14648433 | 0.92 | DPP4 (0.85) | DPP4DPP8DPP9MAP3K12 | |
| SCHEMBL3928376 | 0.85 | DPP4 (1.00) | DPP4DPP8DPP9MAP3K12 | |
| SCHEMBL3928382 | 0.85 | DPP4 (1.00) | DPP4DPP8DPP9MAP3K12 | |
| SCHEMBL3923070 | 0.79 | DPP4 (1.00) | DPP4DPP8DPP9MAP3K12 | |
| SCHEMBL3923073 | 0.79 | DPP4 (1.00) | DPP4DPP8DPP9MAP3K12 | |
| SCHEMBL3920628 | 0.78 | DPP4 (0.79) | DPP4DPP8DPP9MAP3K12 | |
| SCHEMBL3920632 | 0.78 | DPP4 (0.79) | DPP4DPP8DPP9MAP3K12 | |
| SCHEMBL3922424 | 0.73 | DPP4 (0.73) | DPP4DPP8MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160058769-A1 | TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL OR NON-ORAL ANTIDIABETIC DRUG | BOEHRINGER INGELHEIM INT (DE) | 2016-03-03 | — | — | US | disclosed |
| US-20160058769-A1 | TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL OR NON-ORAL ANTIDIABETIC DRUG | BOEHRINGER INGELHEIM INT (DE) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058769-A1 | TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL OR NON-ORAL ANTIDIABETIC DRUG | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.